AstraZeneca PLC (AZN)vsElectromed Inc (ELMD)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
ELMD
Electromed Inc
$25.10
-2.49%
HEALTHCARE · Cap: $215.16M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 85201% more annual revenue ($58.74B vs $68.86M). AZN leads profitability with a 17.4% profit margin vs 13.1%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 68/100 (B-).
AZN
Buy64
out of 100
Grade: C+
ELMD
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-26.6%
Fair Value
$19.96
Current Price
$25.10
$5.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Growing faster than its price suggests
Every $100 of equity generates 20 in profit
16.3% revenue growth
Earnings expanding 45.5% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : ELMD
The strongest argument for ELMD centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 16.3% demonstrates continued momentum. PEG of 0.35 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : ELMD
The primary concerns for ELMD are P/E Ratio, Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while ELMD is a growth play — different risk/reward profiles.
ELMD carries more volatility with a beta of 0.32 — expect wider price swings.
ELMD is growing revenue faster at 16.3% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
ELMD scores higher overall (68/100 vs 64/100) and 16.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Electromed Inc
HEALTHCARE · MEDICAL DEVICES · USA
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?